As a flagellated, protozoan parasite, Trypanosoma cruzi can lead to Chagas’ Disease which is endemic in Latin America. T. cruzi infection is a chronic, asymptomatic, incurable, and potentially fatal disease. Transmission routes contain vector transmission (red beetles), congenital transmission, transplantation, and blood transfusion.
In the life cycle of T. cruzi exists three morphologic forms: epimastigote (multiplying form in the midgut of the vector insect), amastigote (multiplying inter-cellular form in mammalian objects); and trypomastigote (nondividing extracellular form in insect feces and mammalian blood). Most T. cruzi proteins are expressed in all three morphologic forms.
Application of Trypanosoma cruzi Antigen
ABBOTT PRISM Chagas Assay
The ABBOTT PRISM Chagas Disease Test is an in vitro chemiluminescent enzyme immunoassay (CLIA) approved by FDA, and it provides a qualitative test for the detection of antibodies to T. cruzi, the etiological agent of Chagas disease, in human serum and plasma samples.
The ABBOTT PRISM Chagas Disease Test is provided on the basis of recombinant FP3, FP6, FP10, and TcF antigens from Escherichia coli. These four hybrid recombinant proteins represent a total of at least 14 different antigenic regions and three major morphologic forms. In addition, these recombinant proteins include antigens recognized by antibodies to acute T. cruzi infection and chronic Chagas disease in humans.
ABBOTT ESA Chagas Assay
ABBOTT ESA Chagas assay is another approved kit, which is an in vitro enzyme strip assay designed for the qualitative testing of antibodies to T. cruzi. It is designed to provide an additional, more specific test for human serum or plasma samples that repeatedly reactive for antibodies to T. cruzi with the approved T screening test. The kit is also developed on the basis of recombinant T. cruzi antigens including FP10, FP6, FP3, and TcF expressed in E. coli.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Trypanosoma Antigen